The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 3 endocrinologydiseases
metformin 59 endocrinologydiseasesdrugs
obesity 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
metformin 57 Title: International Urology and NephrologyThe impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysisYang LiLiyi HuQinghong XiaYongqiang
metformin 318 3/2017Publication date (pmc-release): 3/2017Publication date (ppub): /2017AbstractPurposeThe effects of metformin on the prognosis of kidney cancer patients with diabetes are in controversial. The present study is
metformin 469 patients with diabetes are in controversial. The present study is conducted to classify the association of metformin use with the survival of patients with kidney cancer.MethodsElectronic databases, namely PubMed and
metformin 975 meta-analysis, including 254,329 kidney cancer patients. The combined HR suggested that the use of metformin could improve the overall survival (OS) (HR 0.643, 95% CI 0.520–0.795, P < 0.001) and cancer-specific
metformin 1242 P = 0.004) in kidney cancer patients. In subgroup analysis, positive associations were found between metformin use and OS/CSS of localized renal cell carcinoma patients (OS: HR 0.634, 95% CI 0.440–0.913, P = 0.014;
metformin 1451 P = 0.014; CSS: HR 0.476, 95% CI 0.295–0.768, P = 0.002). Moreover, we also found that the use of metformin could reduce the risk of death in kidney cancer patients (HR 0.711, 95% CI 0.562–0.899, P = 0.004).ConclusionOur
metformin 1611 patients (HR 0.711, 95% CI 0.562–0.899, P = 0.004).ConclusionOur findings suggest that the use of metformin is in favor of the prognosis of patients with kidney cancers. Further investigations are needed to evaluate
metformin 1753 patients with kidney cancers. Further investigations are needed to evaluate the prognostic value of metformin on kidney cancer patients.IntroductionRenal cell carcinoma (RCC) is recognized as the most common and
metformin 2903 kidney cancer remain unclear. The articles reported by Nayan et al. [[14], [15]] showed that the use of metformin was not associated with the overall survival (OS), cancer-specific survival (CSS), and disease-free
metformin 3113 survival (DFS) of RCC patients. However, Keizman et al. [[16]] found that RCC patients treated with metformin have lower risk of mortality than those without metformin therapy. In addition, another study found
metformin 3171 [[16]] found that RCC patients treated with metformin have lower risk of mortality than those without metformin therapy. In addition, another study found that compared to metformin non-users, metformin use on RCC
metformin 3240 of mortality than those without metformin therapy. In addition, another study found that compared to metformin non-users, metformin use on RCC patients was in favor of better CSS and DFS [[17]]. Thus, the impact
metformin 3261 those without metformin therapy. In addition, another study found that compared to metformin non-users, metformin use on RCC patients was in favor of better CSS and DFS [[17]]. Thus, the impact of metformin on survival
metformin 3354 non-users, metformin use on RCC patients was in favor of better CSS and DFS [[17]]. Thus, the impact of metformin on survival outcomes of patients with kidney cancer was in controversial.To obtain a more comprehensive
metformin 3513 cancer was in controversial.To obtain a more comprehensive estimation of the prognostic significance of metformin in RCC patients, we performed the present meta-analysis to explore the effects of metformin on OS, CSS,
metformin 3605 significance of metformin in RCC patients, we performed the present meta-analysis to explore the effects of metformin on OS, CSS, DFS, and PFS of patients with RCC.Materials and methodsRetrieval of studiesWe performed
metformin 3912 November 2016). The search strategy was based on Mesh headings, key words and text words as follows: “ metformin ” combined with “kidney cancer” or “kidney carcinoma” or “kidney neoplasm” or “renal
metformin 4701 diagnosed as kidney cancer patients with diabetes; (4) articles estimating the association between metformin use and survival of kidney cancer patients; (5) eligible data could be obtained including hazard ratio
metformin 5281 number of patients, amount of male patients, number of patients received surgery therapy, counts of metformin users and metformin non-users, pathological type of kidney cancer (localized RCC or metastatic RCC),
metformin 5301 amount of male patients, number of patients received surgery therapy, counts of metformin users and metformin non-users, pathological type of kidney cancer (localized RCC or metastatic RCC), HR and 95% CI of the
metformin 5543 outcomes.Statistical analysisPooled HR and its corresponding 95% CI were used to evaluate the association of metformin use with OS, PFS, DFS, and CSS of kidney cancer. It suggested poor prognosis when HR was larger than
metformin 6646 Detailed search strategy is shown in Fig. 1. The main characteristics of the eligible studies for metformin use on kidney cancer patients are summarized in Tables 1 and 2. A total of 254,329 patients were included,
metformin 9228 therapybMetformin users versus antidiabetic therapy non-usersOutcomes of all-caused mortalityThe association of metformin use with OS of kidney cancer patients was reported in six articles involving 253,150 patients [[1],
metformin 9560 (4484 patients) [[16], [18]]. The pooled HR showed that compared to patients without being exposed to metformin , a reduced risk of mortality was observed in patients exposed to metformin [HR (95% CI) 0.41 (0.38–0.45),
metformin 9635 without being exposed to metformin, a reduced risk of mortality was observed in patients exposed to metformin [HR (95% CI) 0.41 (0.38–0.45), P < 0.001]. However, there was significant heterogeneity among these
metformin 10391 the heterogeneity. In addition, subgroup analyses were used to identify the different influences of metformin use on populations from different regions of the world and patients with or without metastases. We found
metformin 10579 without metastases. We found a significant reduced risk of death in localized RCC patients exposed to metformin [HR (95% CI):0.634 (0.440–0.913), I2 = 0.00%, Pheterogeneity = 0.375; Z = 2.45, P = 0.014,
metformin 10741 Pheterogeneity = 0.375; Z = 2.45, P = 0.014, Fig. 2b]. The results also showed that the use of metformin was in favor of weakening the risk of death for North American RCC patients [HR (95% CI) 0.711 (0.562–0.899),
metformin 11173 (0.449–0.841), I2 = 76.5%, Pheterogeneity = 0.039; Z = 3.26, P = 0.001].Fig. 2Association between metformin exposure and OS of kidney cancer patients. a All studies with excluding the source of heterogeneity;
metformin 11453 associated with North American patientsOutcomes of kidney cancer-specific survivalThe relationship of metformin use with kidney cancer-specific mortality was studied in five articles recruiting 2228 patients [[14],
metformin 11880 Although the pooled HR suggested that no association was observed between CSS and patients exposed to metformin or not, there was a high degree of heterogeneity [HR (95% CI) 0.830 (0.658–0.1.048), I2 = 57.8%,
metformin 12364 And the risk of kidney cancer specific due to kidney carcinoma was decreased in patients treated with metformin in comparison with the patients without use of metformin [HR (95% CI) 0.618 (0.446–0.858), I2 = 28.5%,
metformin 12421 carcinoma was decreased in patients treated with metformin in comparison with the patients without use of metformin [HR (95% CI) 0.618 (0.446–0.858), I2 = 28.5%, Pheterogeneity = 0.232; Z = 2.87, P = 0.004,
metformin 12590 Pheterogeneity = 0.232; Z = 2.87, P = 0.004, Fig. 3a]. Moreover, in the subgroup analysis, the use of metformin reduced the risk of death in patients with localized RCC patients [HR (95% CI) 0.476 (0.295–0.768),
metformin 12825 Pheterogeneity = 0.331; Z = 3.04; P = 0.002, Fig. 3b]. No associations were found between the use of metformin and the North American populations with RCC [HR (95% CI) 0.606 (0.349–1.053), I2 = 0.00%, Pheterogeneity = 0.293;
metformin 13003 (0.349–1.053), I2 = 0.00%, Pheterogeneity = 0.293; Z = 1.78; P = 0.076].Fig. 3Relationship of metformin exposure with CSS of kidney cancer patients. a All studies with omission of the studies contributed
metformin 13453 RCC patients) [[15], [17], [19], [20]]. The pooled HRs showed that there was no associations between metformin use and PFS/DFS of RCC patients [PFS: 0.919 (0.791–1.067), I2 = 0.00%, Pheterogeneity = 0.388,
metformin 14218 heterogeneity)].DiscussionKey findingsThe present meta-analysis is the first to discover the association between metformin and kidney cancer patients. The results showed that metformin could improve the OS [HR (95% CI) 0.643
metformin 14280 first to discover the association between metformin and kidney cancer patients. The results showed that metformin could improve the OS [HR (95% CI) 0.643 (0.520–0.795), P < 0.001] and CSS [HR (95% CI) 0.618 (0.446–0.858),
metformin 14521 patients with kidney cancer. In the subgroup analysis, we also found that in kidney cancer patients, metformin users could have better prognosis (OS) than metformin non-users. In addition, the subgroup analysis
metformin 14575 we also found that in kidney cancer patients, metformin users could have better prognosis (OS) than metformin non-users. In addition, the subgroup analysis also suggested that compared to patients treated without
metformin 14688 non-users. In addition, the subgroup analysis also suggested that compared to patients treated without metformin , OS and CSS were both improved in localized RCC patients treated with metformin, which was not found
metformin 14768 patients treated without metformin, OS and CSS were both improved in localized RCC patients treated with metformin , which was not found in metastatic RCC. Nevertheless, our current meta-analysis did not show association
metformin 14886 was not found in metastatic RCC. Nevertheless, our current meta-analysis did not show association of metformin with the DFS and PFS of kidney cancer.Comparison with other studiesThe results of our meta-analysis
metformin 15145 previous studies. It has been reported by Tseng et al. [[1]] that better OS was associated with the use of metformin in kidney cancer patients. Moreover, Keizman et al. [[16]] and Psutka et al. [[19]], respectively, found
metformin 15421 was reduced in cancer patients. Up to data, only one study related to localized RCC demonstrated that metformin could decrease the risk of kidney cancer-specific death in RCC patients [[17]]. However, another three
metformin 15559 kidney cancer-specific death in RCC patients [[17]]. However, another three articles identified that metformin showed no association with the OS of both localized and metastatic RCC patients [[14], [15], [18]].
metformin 15767 [18]]. Meanwhile, four researches associated with localized and metastatic RCC suggested that the use of metformin had no effects on the CSS of patients with RCC [[14], [17], [19], [20]]. In addition, among five studies
metformin 15974 studies on DFS, only one study published by Cheng et al. [[17]] showed positive association between metformin use and the DFS of localized RCC patients, which was in contrast to our findings. Additionally, two
metformin 16135 was in contrast to our findings. Additionally, two studies on PFS found that there were no effects of metformin on the PFS of metastatic RCC patients [[16], [18]].Strengthens and weaknessWe are the first to explore
metformin 16265 metastatic RCC patients [[16], [18]].Strengthens and weaknessWe are the first to explore the influence of metformin on the prognosis of kidney cancer patients with diabetes. And in this meta-analysis, localized RCC and
metformin 16495 are both included. Moreover, we also conducted subgroup analysis to identify the different effects of metformin on localized and metastatic RCC. However, there are limitations in our meta-analysis. The sample size
metformin 17057 contribute to the heterogeneity of this meta-analysis and play a great role in identifying the influences of metformin on the prognosis of Asian kidney cancer patients. The subgroup analysis in Fig. 2c also has shown that
metformin 17212 patients. The subgroup analysis in Fig. 2c also has shown that only one article reported the effects of metformin on the OS of Asian kidney cancer patients. Therefore, further studies are needed to explore the association
metformin 17338 Asian kidney cancer patients. Therefore, further studies are needed to explore the association between metformin use and various populations to exclude the heterogeneity. And the patients of the eligible studies are
metformin 17561 diagnosed as localized RCC, which makes it difficult to investigate the association between the use of metformin and outcomes of metastatic RCC patients. In addition, the clinical information extracted from the eligible
metformin 17794 limited, which makes it difficult to make further subgroup analysis to analyzed whether the impacts of metformin on kidney cancer patients are related with age, sex, and other characteristics.ConclusionThe current
metformin 17944 with age, sex, and other characteristics.ConclusionThe current meta-analysis suggests that the use of metformin could improve the OS and CSS of kidney cancer patients, especially localized RCC patients. However,
metformin 18187 meta-analysis, further investigations are needed to be conducted to identify the different effects of metformin on patients with localized and metastatic RCC
Select Disease Character Offset Disease Term Instance
diabetes mellitus 2207 and obesity [[3]]. In addition, several studies have demonstrated that kidney cancer patients with diabetes mellitus have poorer survival compared with those without diabetes mellitus [[4]–[6]]. Another three articles
diabetes mellitus 2274 that kidney cancer patients with diabetes mellitus have poorer survival compared with those without diabetes mellitus [[4]–[6]]. Another three articles also found that diabetes mellitus may be an independent risk factor
diabetes mellitus 2344 survival compared with those without diabetes mellitus [[4]–[6]]. Another three articles also found that diabetes mellitus may be an independent risk factor for the survival of kidney cancer patients [[7]–[9]].Metformin,
obesity 2112 mostly attributed to the widely use of diagnostic imaging and the increasing rates of hypertension and obesity [[3]]. In addition, several studies have demonstrated that kidney cancer patients with diabetes mellitus

You must be authorized to submit a review.